International Survival Follow-up of Patients Enrolled In the Renal Cell Carcinoma Evaluation of Adjuvant Oncophage® Treatment in the Antigenics C-100-12 (Part I) Protocol (INSPIRE). - INSPIRE
- Conditions
- Renal cell carcinoma.MedDRA version: 9.1Level: LLTClassification code 10038395Term: Renal carcinoma
- Registration Number
- EUCTR2007-007460-22-SE
- Lead Sponsor
- Antigenics Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 436
To be eligible, patients must have:
1.Participated in the Antigenics C-100-12 (Part I) protocol and terminated the study with the last survival status reported as alive” and due to administrative study closure”.
2.Signed an informed consent to participate in the C-100-27 Survival Follow-up protocol, and be willing to receive contact from a representative from the protocol investigative study centers and/or any subsequently identified co-investigator sites where patients consent to continued survival follow-up and/or a member from a company designated by the Sponsor every 6 months if no disease recurrence and every 3 months if disease has recurred.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
The study has no exclusion criteria.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method